Compare Novartis AG (NVS) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Paychex, Inc. — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Paychex, Inc. trades at $104.29 (market cap $36.15B). The key difference: Novartis AG is far larger — about 7.6× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.69%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Paychex, Inc. for 56 Days on average.
| NVS | PAYX | |
|---|---|---|
Market Cap | $274.00B | $36.15B |
Volume | 1,852,137 | 2,429,537 |
Sector | Health | Industrials |
52-Week High | $168.62 | $128.59 |
52-Week Low | $121.80 | $85.57 |
Typical Hold Time | 82 Days | 56 Days |
Enterprise Value | $315.32B | $39.84B |
Dividend Yield | 3.31% | 4.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Paychex (PAYX) trades at $104.46, up 3.41% today, but remains in a bearish technical trend with resistance near $103. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.34, and maintains robust profitability with a net margin of 27.35%. Recent news highlights concerns over labor market cooling and dividend sustainability despite consistent payouts.
Outlook is mixed: solid fundamentals and a $111 consensus price target suggest upside, but bearish technicals and competitive pressures pose risks. The stock offers income via dividends, yet investor sentiment is cautious amid earnings quality questions and macroeconomic headwinds affecting small business employment trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
